In the past week, ATOS stock has gone up by 5.11%, with a monthly gain of 6.67% and a quarterly surge of 10.77%. The volatility ratio for the week is 4.30%, and the volatility levels for the last 30 days are 5.90% for Atossa Therapeutics Inc The simple moving average for the past 20 days is 11.80% for ATOS’s stock, with a 20.81% simple moving average for the past 200 days.
Is It Worth Investing in Atossa Therapeutics Inc (NASDAQ: ATOS) Right Now?
Company’s 36-month beta value is 1.20.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ATOS is 125.71M, and currently, short sellers hold a 10.23% ratio of that floaft. The average trading volume of ATOS on August 29, 2024 was 1.06M shares.
ATOS) stock’s latest price update
Atossa Therapeutics Inc (NASDAQ: ATOS)’s stock price has soared by 4.35 in relation to previous closing price of 1.38. Nevertheless, the company has seen a gain of 5.11% in its stock price over the last five trading days. globenewswire.com reported 2024-08-28 that SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,071,391) directed to compositions comprising endoxifen (in free base or salt forms) and an enteric material in which at least 90 percent of the endoxifen is (Z)-endoxifen. The patent also covers methods of administering those compositions to patients. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Analysts’ Opinion of ATOS
Many brokerage firms have already submitted their reports for ATOS stocks, with Maxim Group repeating the rating for ATOS by listing it as a “Buy.” The predicted price for ATOS in the upcoming period, according to Maxim Group is $2 based on the research report published on January 26, 2018 of the previous year 2018.
ATOS Trading at 13.28% from the 50-Day Moving Average
After a stumble in the market that brought ATOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.66% of loss for the given period.
Volatility was left at 5.90%, however, over the last 30 days, the volatility rate increased by 4.30%, as shares surge +10.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.68% upper at present.
During the last 5 trading sessions, ATOS rose by +4.38%, which changed the moving average for the period of 200-days by +125.20% in comparison to the 20-day moving average, which settled at $1.2950. In addition, Atossa Therapeutics Inc saw 63.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATOS starting from Finn Jonathan, who purchase 25,000 shares at the price of $1.77 back on Apr 10 ’24. After this action, Finn Jonathan now owns 25,000 shares of Atossa Therapeutics Inc, valued at $44,250 using the latest closing price.
WEAVER GREGORY L, the Former EVP, CFO, & Director of Atossa Therapeutics Inc, sale 50,000 shares at $0.65 during a trade that took place back on Nov 15 ’23, which means that WEAVER GREGORY L is holding 55 shares at $32,500 based on the most recent closing price.
Stock Fundamentals for ATOS
The total capital return value is set at -0.38. Equity return is now at value -28.00, with -26.68 for asset returns.
Currently, EBITDA for the company is -31.35 million with net debt to EBITDA at 2.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.35.
Conclusion
In a nutshell, Atossa Therapeutics Inc (ATOS) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
